newsDaiichi Sankyo receives approval for the use of Inavir® to prevent influenza20 December 2013 | By Daiichi SankyoInavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan...
newsDaiichi Sankyo submits supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for new indications19 December 2013 | By Daiichi Sankyo CompanyDaiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism...
newsDaiichi Sankyo launches four new generic drugs through its Daiichi Sankyo Espha Subsidiary13 December 2013 | By Daiichi SankyoDaiichi Sankyo Espha launched two new generic drugs with two new active ingredients and two generic drugs with an additional standard...
newsPhase 3 data show Daiichi Sankyo’s once-daily edoxaban lowered incidence of VTE recurrence and clinically relevant bleeding10 December 2013 | By Daiichi Sankyo CompanyThis analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition...
newsDaiichi Sankyo launches natural tetrahydrobiopterin agent Biopten® Granules 10%29 November 2013 | By Daiichi Sankyo Company,Biopten is a highly pure, chemically synthesized form of natural tetrahydrobiopterin (hereafter, BH4) that occurs naturally in the human body...
newsDaiichi Sankyo’s once-daily edoxaban meets primary efficacy endpoint for stroke prevention and superiority for the principal safety endpoint compared to Warfarin for patients with atrial fibrillation in a phase 3 clinical trial20 November 2013 | By Daiichi Sankyo EuropeOnce-daily edoxaban, evaluated in two treatment arms achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism...
newsDaiichi Sankyo selects research partners for TaNeDS Collaborative Drug Discovery project23 October 2013 | By Daiichi Sankyo CompanyThe researchers were selected from universities and public research centers in Japan...
newsAstraZeneca and Daiichi Sankyo announce iPhone app for reflux esophagitis18 September 2013 | ByDaiichi Sankyo Co., Ltd. and AstraZeneca K.K. are working to educate the public about reflux esophagitis through a campaign entitled “Do you experience heartburn or acid reflux?”
newsDaiichi Sankyo’s once-daily edoxaban shows comparable efficacy and superiority for the principal safety endpoint compared to warfarin in a Phase 3 study for the treatment of symptomatic VTE and prevention of its recurrence1 September 2013 | By Daiichi SankyoDaiichi Sankyo announced results from the global phase 3 Hokusai-VTE study...
newsDaiichi Sankyo submits application to manufacture and market RANMARK® for treatment of giant cell tumor of bone in Japan29 August 2013 | By Daiichi SankyoDaiichi Sankyo has filed an application for approval in Japan to manufacture and market RANMARK®...
newsDaiichi Sankyo to Expand Its Collaborative Drug Discovery Program to Germany, Switzerland, and Austria29 July 2013 | By Daiichi SankyoDaiichi Sankyo announced that it will expand its Take a New challenge for Drug diScovery Global Program...
newsDaiichi Sankyo announces Phase 3 study results (PRASFIT-Elective study) for the antiplatelet agent prasugrel in Japan12 July 2013 | By Daiichi SankyoResults of a phase 3 clinical study...
newsDaiichi Sankyo submits a New Drug Application in Japan for the antiplatelet agent prasugrel18 June 2013 | By Daiichi SankyoThe application is based on the results of a phase 3 trial...
newsPerosphere and Daiichi Sankyo enter into a clinical trial agreement26 April 2013 | By Daiichi SankyoDaiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
newsDaiichi Sankyo enrolls first patient in Nimotuzumab Phase 3 clinical trials25 April 2013 | By Daiichi SankyoThe first patient has been enrolled in two pivotal phase 3 clinical trials of nimotuzumab...
